Although the OncoScreen Plus assay does not detect PTEN rearrangements, the number of patients with tumor PTEN rearrangements in the Chinese cohort would likely be very low, given that in the global population this subset accounted for only two out of 594 patients with known biomarker results using the FoundationOne®CDx assay (unpublished data). The gene discussed is PTEN; the disease is neoplasm.